Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents

Apoptosis

Volumn 11, Issue 10, 2006, Pages 1747-1760

  Leger, D Y ^a   Liagre, B ^a   Beneytout, J L ^a  

^a UNIVERSITY OF LIMOGES   (France)

Author keywords

Akt; Apoptosis; Erythroleukemia cells; Leflunomide; MAPK

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; DNA FRAGMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ETOPOSIDE; HUMANS; ISOXAZOLES; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 8; NF-KAPPA B; ORGANOPHOSPHORUS COMPOUNDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAUROSPORINE;

EID: 33748547765     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-9439-7     Document Type: Article

References (55)

1. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903-911
2. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356-361
3. Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497-502
4. Senel S, Kaya E, Aydogdu I, Erkurt MA, Kuku I (2006) Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature. Rheumatol Int (in press)
5. Smolen JS, Kalden JR, Scott DL, et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1353:259-266
6. Smolen JS, Emery P, Kalden JR, et al (2004) The efficacy of leflunomidemonotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol 71:13-20
7. Greene S, Watanabe K, Braatz-Trulson J, Lou L (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50:861-867.
8. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochem 35:1270-1273
9. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971-979
10. Ghosh S, Zheng Y, Jun X, et al (1998) Alpha-cyano-beta-hydroxy-beta- methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin Cancer Res 4:2657-2668
11. Xu X, Shen J, Mall JW, et al (1999) In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol 58:1405-1413
12. Liagre B, Vergne-Salle P, Corbiere C, Charissoux JL, Beneytout JL (2004) Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression. Arthritis Res Ther 6:R373-383
13. Liagre B, Bertrand J, Leger DY, Beneytout JL (2005) Diosgenin, a plant steroid, induces apoptosis in COX-2 deficient K562 cells with activation of the p38 MAP kinase signalling and inhibition of NF-kappaB binding. Int J Mol Med 16:1095-1101
14. Leger DY, Liagre B, Beneytout JL (2006) Role of MAPKs and NF-kappaB in diosgenin-induced megakaryocytic differentiation and subsequent apoptosis in HEL cells. Int J Oncol 28:201-207
15. Leger DY, Liagre B, Corbiere C, Cook-Moreau J, Beneytout JL (2004) Diosgenin induces cell cycle arrest and apoptosis in HEL cells with increase in intracellular calcium level, activation of cPLA2 and COX-2 overexpression. Int J Oncol 25:555-562
16. Spodnik JH, Wozniak M, Budzko D, et al (2002) Mechanism of leflunomide-induced proliferation of mitochondria in mammalian cells. Mitochondrion 2:163-179
17. Cao WW, Kao PN, Chao AC, Gardner P, Ng J, Morris RE (1995) Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant 14:1016-1030
18. Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Sci 298:1911-1912
19. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Sci 270:1326-1331
20. Thompson JE, Thompson CB (2004) Putting the rap on Akt. J Clin Oncol 22:4217-4226
21. Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997
22. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
23. van Roon EN, Yska JP, Raemaekers J, Jansen TL, van Wanrooy M, Brouwers JR (2004) A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy. J Pharm Biomed Anal 36:17-22
24. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H (1997) Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 11:479-484
25. Milella M, Kornblau SM, Estrov Z, et al (2001) Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108:851-859
26. Platanias LC (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101:4667-4679
27. Tamemoto H, Kadowaki T, Tobe K, et al (1992) Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J Biol Chem 267:20293-20297
28. Favata MF, Horiuchi KY, Manos EJ, et al (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632
29. Zhang Y, Huang Y, Rishi AK, et al (1999) Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp Cell Res 247:233-240
30. Iwama K, Nakajo S, Aiuchi T, Nakaya K (2001) Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca2+-dependent production of superoxide. Int J Cancer 92:518-526
31. Kutuk O, Pedrech A, Harrison P, Basaga H (2005) Pramanicin induces apoptosis in Jurkat leukemia cells: a role for JNK, p38 and caspase activation. Apoptosis 10:597-609
32. Brantley-Finley C, Lyle CS, Du L, et al (2003) The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 66:459-469
33. Wang D, Li H, Yuan H, et al (2005) Humanin delays apoptosis in K562 cells by downregulation of P38 MAP kinase. Apoptosis 10:963-971
34. Huang M, Wang Y, Collins M, Mitchell BS, Graves LM (2002) A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools. Mol Pharmacol 62:463-472
35. Nagata Y, Takahashi N, Davis RJ, Todokoro K (1998) Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 92:1859-1869
36. Witt O, Sand K, Pekrun A (2000) Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 95:2391-2396
37. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G (1999) NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 96:9136-9141
38. Manna SK, Mukhopadhyay A, Aggarwal BB (2000) Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 165:5962-5969
39. Vergne-Salle P, Leger DY, Bertin P, Treves R, Beneytout JL, Liagre B (2005) Effects of the activemetabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine 31:335-348
40. Hammerman PS, FoxCJ, Birnbaum MJ, Thompson CB (2005) Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 105:4477-4483
41. Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667-676.
42. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905-2927
43. Knuefermann C, Lu Y, Liu B, et al (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205-3212
44. Kolitz JE, George SL, Dodge RK, et al (2004) Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22:4290-4301
45. Russo D, Malagola M, de Vivo A, et al (2005) Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol 131:172-179
46. Yu C, Dai Y, Dent P, Grant S (2002) Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. Cancer Biol Ther 1:674-682
47. Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S (2005) Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 4:457-470
48. Mathews V, George B, Lakshmi KM, et al (2005) Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood (in press)
49. Latagliata R, Bongarzoni V, Carmosino I, et al (2006) Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol 17:281-285
50. Dai Y, Rahmani M, Pei XY, et al (2005) Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105:1706-1716
51. Lee SM, Lee CT, Kim YW, Han SK, Shim YS, Yoo CG (2006) Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett (in press)
52. Larribere L, Khaled M, Tartare-Deckert S, et al (2004) PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 11:1084-1091
53. Tabellini G, Cappellini A, Tazzari PL, et al (2005) Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 202:623-634
54. Cardone MH, Roy N, Stennicke HR, et al (1998) Regulation of cell death protease caspase-9 by phosphorylation. Sci 282:1318-1321
55. Amaravadi R, Thompson CB (2005) The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115:2618-2624